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a b s t r a c t 
The protease ﬁbroblast activation protein (FAP) is a speciﬁc marker of activated mesenchymal cells in
tumour stroma and ﬁbrotic liver. A speciﬁc, reliable FAP enzyme assay has been lacking. FAP’s unique
and restricted cleavage of the post proline bond was exploited to generate a new speciﬁc substrate
to quantify FAP enzyme activity. This sensitive assay detected no FAP activity in any tissue or ﬂuid
of FAP gene knockout mice, thus conﬁrming assay speciﬁcity. Circulating FAP activity was ∼20- and
1.3-fold less in baboon than in mouse and human plasma, respectively. Serum and plasma contained
comparable FAP activity. In mice, the highest levels of FAP activity were in uterus, pancreas, submaxillary
gland and skin, whereas the lowest levels were in brain, prostate, leukocytes and testis. Baboon organs
high in FAP activity included skin, epididymis, bladder, colon, adipose tissue, nerve and tongue. FAP
activity was greatly elevated in tumours and associated lymph nodes and in fungal-infected skin of
unhealthy baboons. FAP activity was 14- to 18-fold greater in cirrhotic than in non-diseased human
liver, and circulating FAP activity was almost doubled in alcoholic cirrhosis. Parallel DPP4 measurements
concorded with the literature, except for the novel ﬁnding of high DPP4 activity in bile. The new FAP
enzyme assay is the ﬁrst to be thoroughly characterised and shows that FAP activity is measurable in
most organs and at high levels in some. This new assay is a robust tool for speciﬁc quantitation of FAP
enzyme activity in both preclinical and clinical samples, particularly liver ﬁbrosis. 
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p. Introduction 
Proteases are increasingly recognised as important regulatory 
olecules [ 1 ]. Fibroblast activation protein (FAP) belongs to the S9 
amily of proteases, which also contains the similar enzymes dipep- 
idyl peptidase 4 (DPP4), DPP8, DPP9 and prolyl endopeptidase (PEP) 
 2 ]. All of these enzymes share the unique ability to cleave the post 
roline bond, which is usually resistant to degradation. Recently, this 
nzyme family has stimulated great pharmaceutical interest, as DPP4 
nhibitors are a successful therapy for type 2 diabetes [ 3 ] and have 
he potential to treat other conditions [ 4 , 5 ]. 
FAP is a constitutively active serine protease that exists as a dimer 
oth on the cell surface and in a soluble, circulating form in the blood. 
AP can hydrolyse both dipeptidase and endopeptidase substrates, 
hich include natural X-Pro-containing bioactive peptides [ 6 ] and 
enatured collagen [ 7 , 8 ] and α2-antiplasmin [ 9 , 10 ]. It is thought that
AP is generally absent from normal adult tissue but has increased ex- 
ression during embryogenesis [ 11 ], tumourigenesis [ 12 –14 ], tissue 
amage and wound healing, ﬁbrosis [ 7 , 15 ] and inﬂammation [ 16 , 17 ].
s FAP is up-regulated in stromal ﬁbroblasts of over 90% of malignant 
pithelial tumours but not in benign tumours [ 18 ], it has become a 
otential biomarker and therapeutic target for tumour stroma [ 19 –
1 ]. 
DPP4 is related transmembrane dimeric glycoprotein that cleaves 
he post proline bond but acts only as a dipeptidyl peptidase. It is 
 ubiquitous enzyme, found on most epithelial cells, especially in 
iver, kidney and gut, on capillary endothelial cells in most organs 
nd on most lymphocytes in immune organs such as thymus, spleen 
nd lymph node [ 22 –25 ]. In contrast to FAP, many natural DPP4 sub- 
trates are known, including gastric hormones [ 26 ], neuropeptides 
 27 , 28 ], and chemokines [ 29 , 30 ]. Soluble DPP4 is present in plasma,
erum, seminal and synovial ﬂuids, as has been reviewed [ 22 , 31 ] and 
oluble DPP4 levels are associated with a variety of human conditions 
uch as psoriasis [ 32 ], chronic fatigue [ 33 ], tuberculosis [ 34 ] and hep-
titis C virus (HCV) [ 35 , 36 ]. Circulating DPP4 activity is elevated in 
ome tumours [ 37 , 38 ] but reduced in others [ 39 –41 ], so the level
ay be tumour-type dependent. It has also been reported to be both 
ncreased [ 42 , 43 ] and decreased [ 44 , 45 ] in type 2 diabetes patients.
s with FAP, the regulatory process or sheddase activity by which the 
oluble form of the enzyme is released from the cell is unknown. 
In contrast to DPP4, little is known about the normal physiological 
unction of either cellular or circulating FAP. Speciﬁcally identifying 
oth the source and activity of soluble FAP has been difﬁcult due 
o its dual enzyme activity, and to date all FAP synthetic substrates 
re also hydrolysed by DPP4 and / or PEP [ 46 ]. Up to now, analysis 
f FAP content in tissue samples has relied on mRNA measurements 
 47 , 48 ] or the use of antibodies, where few are reliable for mouse 
AP [ 49 ]. FAP has been targeted in cancer models using chemical 
nhibitors [ 50 ], antibodies [ 51 ], toxins [ 52 ], pro-drugs [ 19 ], T-cells 
 53 ] and RNA interference [ 54 ], but basal, endogenous FAP expression 
as only recently been examined in normal tissue [ 55 , 56 ] and this has 
hallenged the dogma that FAP is only expressed in diseased tissue. 
hus, FAP’s basal expression pattern and normal physiological activity 
roﬁle require close examination to better understand the role of this 
rotease. 
Our hypothesis is that FAP is present and active in measureable 
mounts in some normal tissues and the aim of the present study 
as to utilise a new FAP-speciﬁc substrate, 3144-AMC, to quantify 
AP expression in mouse, baboon and human ﬂuids and tissues. We 
ought to show that this assay is speciﬁc, sensitive and efﬁcient at 
uantifying both the soluble and cell-bound forms of FAP from a range 
f tissues in three different mammalian species. The poor availability 
f fresh human tissue was overcome by obtaining an extensive range 
f fresh tissues from a closely-related primate, the baboon. We also 
uantiﬁed FAP activity in diseased baboon and human tissue and 
lasma as a preliminary exploration of its use as a biomarker, while DPP4 activity was measured as a comparator. FAP is an intriguing 
protein and the heavy focus on targeting it in cancer therapy needs 
to be reconciled with its normal physiological function, which is not 
fully understood. Here we delineate locations and relative quantities 
of FAP enzyme activity in a wide range of settings to develop an 
understanding of the roles of this unique enzyme. 
2. Results 
FAP is present in a soluble form in human plasma [ 10 ]. A novel 
FAP substrate, 3144-AMC [ 57 ], was used in this study to quantify FAP 
activity in non-diseased plasma from three species. During optimisa- 
tion of this soluble assay we found that the greatest FAP activity came 
from volumes of mouse, baboon or human plasma of 0.5–1 μl ( Fig. 
1 A–C), so 1 μl was used for all subsequent assays. Clear inverse dose 
responses were produced by plasma volumes that were greater than 
optimal. All samples tested for enzyme activity in mouse, baboon and 
humans are listed in Supplemental Tables 1–3 , respectively. 
The second aim was to verify the speciﬁcity of substrate 3144- 
AMC for FAP, using FAP-deﬁcient samples including plasma from FAP 
gene knockout (gko) mice [ 58 ] and plasma from humans carrying a 
FAP gene variant [ 59 ]. Similar quantities of FAP activity were detected 
in wt and DPP4 gko mouse plasma ( Fig. 2 A), which is consistent with 
our previous data showing no compensatory change in FAP expres- 
sion in liver when DPP4 is absent [ 60 ]. In contrast, FAP gko mouse 
plasma had no detectable activity while heterozygous (het) mice had 
reduced FAP enzymatic levels ( Fig. 2 A). We separately identiﬁed FAP- 
deﬁcient individuals expressing a Ser363Leu variant FAP protein that 
lacks functional FAP activity [ 59 ]. Plasma FAP activity levels from the 
heterozygous person (FAP + / −) were less than half that of healthy 
volunteers, whereas neither of the two FAP Ser363Leu homozygous 
individuals (FAP −/ −) had detectable FAP activity ( Fig. 2 B). The four 
points on the graph for the mutation-affected individuals are from 
four separate blood draws over a 3-h period post glucose bolus in- 
gestion. All FAP activity data for mouse, baboon and human ﬂuids is 
given in Supplemental Table 4 . 
3144-AMC was then used to assess FAP activity in other primate 
ﬂuids. Enzymatic levels in baboon plasma and serum were approx- 
imately 300 pmol AMC / min / ml but no detectable FAP activity was 
present in baboon urine or bile from three animals ( Fig. 3 A), despite 
various volumes of both ﬂuids (0.1–50 μl) being tested (data not 
shown). Although there was ∼2-fold variation between individuals, 
humans had greater average FAP activity than baboons. Interestingly, 
it was found that FAP activity levels were equal between plasma 
and serum in both baboons and humans ( Fig. 3 A), indicating that the 
presence of platelets, ﬁbrinogen and other clotting factors do not af- 
fect this FAP assay. Subsequent FAP graphs contain average data for 
plasma and serum if both were analysed from one individual. The 
activity levels of DPP4 in these samples were then measured using 
the ﬂuorogenic substrate H-Gly-Pro-AMC. Baboon plasma and serum 
had DPP4 activity of ∼2785 pmol AMC / min / ml and human plasma 
and serum had similar levels to baboon ( Fig. 3 B). Baboon urine had 
barely detectable DPP4 activity, whereas bile had high levels. Further 
examination of bile from three species showed that mice had higher 
levels of bile DPP4 activity than a mixed cohort of baboons, with hu- 
man bile from liver transplant recipients having the least DPP4 activ- 
ity (one-way ANOVA p -value = 0.0024; Fig. 3 C). Both soluble FAP and 
DPP4 quantitation was unaffected by 12 freeze / thaw cycles of plasma 
( Supplemental Fig. 1 ). All DPP4 activity data for mouse, baboon and 
human ﬂuids is given in Supplemental Table 5 . 
A direct comparison shows that circulating FAP activity levels dif- 
fer between species, with wt mice having approximately 19- and 
15-fold greater FAP activity than baboons and humans, respectively 
( Fig. 4 A). Baboon and human plasma, with average FAP activity lev- 
els of 315 and 404 pmol AMC / min / ml, respectively, are comparable. 
Total plasma protein quantitation in all three species was in line with 
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Fig. 1. Volume optimization for circulating FAP activity assay. Determining an optimal 
volume of mouse (A), baboon (B) and human plasma (C) in FAP enzyme assays. The 
minimum volume was 5 μl of diluted or undiluted plasma. FAP activity was expressed 
as pmol AMC released from substrate 3144-AMC / min / ml. 1 μl was chosen as an 
optimal volume for ﬂuids of all species. Horizontal bars are means and error bars 
depict SEM. n = 2 (A and B) or 3 (C). 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Speciﬁcity of substrate 3144-AMC for circulating FAP. FAP activity was assayed 
in 1 μl of plasma from (A) mice, ( n = 3–6) from four genetic backgrounds and (B) 
healthy adult humans (FAP + / + , n = 5), a heterozygous FAP activity-deﬁcient indi- 
vidual (FAP + / −) and two separate homozygous individuals (FAP −/ − 1, FAP −/ − 2). 
FAP activity was expressed as pmol AMC released from substrate 3144-AMC / min / ml. 
Horizontal bars are means and error bars depict SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 published values, with protein concentration for primate and mouse
plasma at ∼70 and ∼42 mg / ml, respectively (data not shown). DPP4
enzymatic levels were then measured in these ﬂuids and wt and FAP
gko mice showed equal levels of plasma DPP4 activity while DPP4 gko
mice had little activity ( Fig. 4 B). The average DPP4 activities in baboon
and human plasma were similar, at ∼3100 and ∼2590 pmol AMC /
min / ml, respectively ( Fig. 4 B). In contrast to FAP, where mice exhib-
ited the highest circulating activity levels, serum DPP4 activity was
greater in primates than in mice ( p = 0.0012 for human DPP4 com-
pared to wt mouse). 
The differing activity levels of soluble FAP across species promptedan investigation into protein sequence similarities. The predicted ba-
boon FAP protein sequence was aligned with that of human, mouse,
chimpanzee and rat ( Supplemental Fig. 2 ). Human FAP was calculated
to be 99.61% identical to baboon FAP and 89.61% identical to mouse
FAP by ClustalW analysis. Considering the enzymatic hydrolase do-
main alone, the identity between human FAP and that of baboon and
mouse rose to 100% and 92.61%, respectively. 
Having shown that 3144-AMC can speciﬁcally detect circulating
FAP, the aim was then to examine tissue-derived FAP activity in organ
homogenates. FAP activity was measured in previously homogenised
[ 25 ] organs from wt and FAP gko mice ( Fig. 5 ). Initial examination
showed greatest FAP activity in mouse uterus, pancreas, submaxil-
lary gland and skin, followed by lymph node, ovary, skeletal muscle,
adrenal and bone marrow. Greater numbers of these high-FAP organs
were then analysed and uterus, pancreas and submaxillary gland re-
mained the three organs in which FAP activity was most abundant
( Fig. 5 ). Notably, these high-FAP organs showed no enzyme activity
in the FAP gko mouse ( Fig. 5 ). Indeed, no FAP enzyme activity was
detected in any organ from the FAP gko mice (data not shown), which
provided additional surety of its speciﬁcity. Organs with the least
FAP activity included prostate, peripheral blood mononuclear cells
(PBMCs) and red blood cells as well as the large vital organs such as
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Fig. 3. Quantitation of FAP and DPP4 activity in ﬂuids. An optimal volume of 1 μl of each ﬂuid was used to examine FAP (A) and DPP4 (B, C) levels in plasma, serum, urine and 
bile. (C) DPP4 activity in bile from non-diseased FAP gko mice ( n = 4), a mixed cohort of baboons ( n = 7) and human cirrhotic liver transplant recipients ( n = 6). Horizontal bars 
are means and error bars depict SEM. 
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irain, heart, liver and lung. All enzyme activity data for mouse, ba- 
oon and human organ homogenates are in Supplemental Table 6 . 
PP4 levels in these mouse organs have been published [ 25 ]. 
To investigate other mammals, non-diseased baboon and human 
rgans were assayed for FAP activity. Variability among baboons was 
vident; however FAP activity was high in skin, similar to mouse and 
lso high in baboon epididymis, bladder, adipose tissue and nerve 
 Fig. 6 A). The large vital organs such as heart, kidney, liver and lung 
ere shown to be lacking in FAP activity, as was observed in mice. 
uman adipose (subcutaneous and omental) and human liver tissue 
ere analysed alongside baboon organs for direct comparison ( Fig. 
 A). Human adipose contained less FAP activity than baboon adipose, 
ut the variability amongst baboon adipose was great. Human liver 
ad low FAP activity ( Fig. 6 A), similar to baboon and mouse liver. 
All of these baboon organs were then tested for DPP4 activity ( Fig. 
 B). As expected, [ 22 ], DPP4 activity was most abundant in kidney, 
ollowed by adrenal, seminal gland, thymus and epididymis, while 
ongue, adipose, pancreas and aorta contained the least DPP4 activ- 
ty. Some baboon organs were from different regions: (a) adipose came from epididymal, pericardial, subcutaneous, urogenital and vis- 
ceral regions, (b) lymph nodes were from the neck and mesentery, (c) 
parotid and submaxillary salivary glands, (d) skeletal muscle included 
bicep, gastrocnemius and gluteus muscles and (e) small intestine in- 
cluded duodenum and jejunum. In each of these ﬁve organs, FAP and 
DPP4 enzyme activity levels were not signiﬁcantly different between 
regions and thus activity data from each are presented together as a 
single organ type. 
Assured of the speciﬁcity of 3144-AMC, we then sought to use this 
substrate in a FAP biomarker assay in altered or diseased states. Ex- 
amining mice, no signiﬁcant FAP activity differences were detected in 
blood drawn in the morning or the evening or during pregnancy ( Fig. 
7 A). Circulating FAP activity levels in the plasma / serum of all avail- 
able baboons showed that the diseased and non-diseased baboons 
were not signiﬁcantly different ( Fig. 7 B), however one diseased male 
animal, with bronchitis and enlarged lymph nodes, had signiﬁcantly 
more circulating FAP activity than all the others. The diseased co- 
hort were simian T-cell lymphotropic virus (STLV)-positive and were 
all euthanased when very ill, often following prolonged weight loss, 
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Fig. 4. Species differences in circulating FAP and DPP4 activity. (A) FAP enzyme activity 
in plasma from mouse, baboon and human. (B) DPP4 enzyme levels in the same set of 
samples. Horizontal bars are means and error bars depict SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 along with other chronic or complicating factors. There was signiﬁ-
cantly less circulating FAP activity in the diabetic baboons than in the
non-diseased animals ( p -value = 0.0317) ( Fig. 7 B). 
As FAP is known to be elevated in solid tumours and other dis-
eases involving tissue damage, speciﬁc enzyme activity was then
examined in selected diseased baboon organs ( Supplemental Table
2 ). A 19-year old female baboon was euthanased due to a large col-
orectal tumour, which proved to be high in FAP activity ( Fig. 7 C).
Similarly, a diseased 13-year old male baboon was euthanased due
to chronic weight loss from a T-cell lymphoma. Two tumour masses
on his pharynx and stomach contained high FAP activity ( Fig. 7 C).
In addition, cervical lymph nodes near the pharyngeal tumour mass
had approximately 8-fold more FAP activity than non-diseased cer-
vical lymph nodes and mesenteric lymph nodes near the stomach
tumour had 52-fold greater FAP activity than non-diseased mesen-
teric lymph nodes. The affected skin of an 18-year old female baboon
with a chronic dermatophyte infection showed 5-fold more FAP ac-
tivity compared to non-diseased skin ( Fig. 7 C). The uterus samples
were all from diseased females of ages 10, 12, 18, 19 and 21 and all
showed variable but high FAP activity levels ( Fig. 7 C), as was observed
in mice ( Fig. 5 ). 
Finally, human liver disease was examined ( Fig. 8 ). FAP activity in
serum from patients with alcoholic liver disease (ALD) ( Supplemental
Table 7 ) was signiﬁcantly increased compared to non-diseased (ND)sera ( Fig. 8 A; p -value = 0.0024). This cirrhotic cohort showed no sig-
niﬁcant difference in DPP4 serum activity (data not shown), highlight-
ing the important role of FAP in liver disease. FAP enzyme activity was
also signiﬁcantly increased in the liver homogenates of patients with
two aetiologies of chronic liver disease with the p -value for ALD and
primary biliary cirrhosis (PBC) of 0.0002 and < 0.0001, respectively,
compared to non-diseased (ND) livers ( Fig. 8 B). 
The increased FAP activity detected in human liver homogenates
by enzyme assays with 3144-AMC concorded with Western blot data
using F19 antibody ( Fig. 8 C–F). On unreduced and unboiled SDS–PAGE
Western blot, F19 detected FAP bands at 150 and 120 kDa in ALD and
PBC livers which were very faint or absent from non-diseased (ND)
livers. Densitometry analysis showed that FAP protein levels were
more than 30-fold greater in ALD livers and approximately 15-fold
greater in PBC livers compared to non-diseased livers. 
3. Discussion 
FAP has been extensively studied in the cancer ﬁeld but has
been difﬁcult to reliably quantify in normal tissues. In this study,
we showed that the novel FAP substrate, 3144-AMC, can form the
basis of a speciﬁc and sensitive assay to quantify endogenous FAP
enzyme activity in diverse mammalian ﬂuids and organs. We proved
assay speciﬁcity by showing no activity in any tissue or ﬂuid from
FAP-deﬁcient mice and humans. Organs rich and poor in FAP activity
were identiﬁed and inter-species differences observed. The diagnostic
potential of this FAP assay was also explored. 
Most previously published data has indicated that FAP is not de-
tectable in normal adult tissue, but readily detectable only in embryos,
tumours, ﬁbrosis and sites of chronic injury and wound healing [ 61 ].
Here, we have shown that FAP is indeed present and active in normal
adult mammalian organs. As previously published, FAP is active in
mouse pancreas [ 62 ], but is also active in uterus, submaxillary gland
and skin. The high FAP activity in skin is likely due to expression
by skin ﬁbroblasts and, while the high FAP activity in baboon lymph
node and ovary is novel, it is poorly understood in terms of activated
mesenchymal cell expression. Some organs showed differential ac-
tivity between the species. Adipose tissue had more FAP activity in
baboon than human, whereas pancreas had the most FAP activity
in mouse. The high FAP protein sequence identity across the three
species suggests that measurements of FAP activity likely reﬂect the
concentration of FAP protein molecules present. However, supporting
studies using puriﬁed recombinant protein from all three species are
required to conﬁrm this. 
Skin, uterus and diseased liver are FAP-active organs of particu-
lar interest. While non-diseased skin was itself high in FAP activity,
the chronic inﬂammation and skin regeneration caused by a dermato-
phyte infection may have caused the increased FAP activity in the skin
of baboon Gi. The high uterine FAP activity may result from the tissue
remodelling and angiogenesis [ 63 ] of oestrus cycle-driven regenera-
tion. The increased FAP expression in diseased liver, which was shown
here to be enzymatically active, may be pro-ﬁbrotic [ 15 , 61 ] and our
assays also showed elevated circulating FAP activity in ALD patients,
suggesting that FAP may become a serum biomarker for liver cirrho-
sis. 
The cellular origin of soluble FAP is unknown. Some cells may
translate it speciﬁcally for secretion or it could be shed from the
surface of certain cells depending upon the local concentration of an
appropriate sheddase. In contrast to DPP4, circulating FAP activity was
15- to 20-fold greater in mice than in primates, suggesting that mice
may have greater expression of such a sheddase. The origin of soluble
DPP4 is also unknown, but is thought to be shed from many cells
including lymphocytes [ 22 ], hepatocytes [ 64 ] and adipocytes [ 65 ].
The important species differences between soluble FAP and DPP4, as
well as their potential sheddases, should be further investigated and
may be exploited in the selective targeting of each enzyme in murine
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Fig. 5. Speciﬁcity of substrate 3144-AMC for tissue-derived mouse FAP. FAP activity was measured in organ homogenates from wt ( n = 1–6) and FAP gko ( n = 2–3) mice. Horizontal 
bars are means and error bars depict SEM. PBMC = peripheral blood mononuclear cells. 
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The DPP4 activity assay data aligns with the literature. However, 
he high level of DPP4 activity observed in bile is novel and consis- 
ent with the potential of DPP4 as a liver injury biomarker [ 36 , 66 , 67 ],
uggesting that circulating DPP4 may be most elevated in diseases in- 
olving impaired bile excretion, such as cholestasis. In a non-diseased 
etting, hepatocytes express DPP4 on their biliary surface [ 24 ] and 
hus can shed the enzyme into the bile but the loss of cell polar- 
ty by damaged hepatocytes in cirrhotic liver [ 68 ] may cause some 
epatocyte-derived DPP4 to enter the blood rather than the bile. 
The inverse FAP activity dose response that occurred with greater 
han optimal plasma volumes may indicate that there is a ﬂuorophore 
uencher or a natural FAP inhibitor that is more active at higher 
lasma concentrations, or perhaps that the substrate is sequestered 
n plasma / serum. Equal levels of FAP and DPP4 in plasma compared 
o serum suggest that both the proteases and any potential inhibitors 
re not depleted by the blood clotting process. This is an important 
bservation as FAP-mediated cleavage of α2-antiplasmin increases 
ts activity, which inhibits ﬁbrinolysis [ 10 , 69 ]. 
Whether elevated FAP in tumour tissue is reﬂected in matched 
erum samples is of diagnostic interest. We observed high cellular 
AP activity in baboon tumour masses as well as in nearby lymph 
odes but the animal with stomach and pharyngeal tumours had 
ne of the lowest circulating FAP measurements. This concords with 
rior reports that circulating FAP levels are lower in cancer patients 
 40 , 70 ]. In contrast, FAP activity was increased in both the serum and the liver of patients with chronic liver disease, which aligns with 
previous studies showing up-regulation of FAP in cirrhotic human 
liver [ 7 , 71 ]. Such data underscores the need to measure both tissue 
and circulating forms of FAP in disease studies and, given that soluble 
FAP is in a functional and active form, its role outside the cell needs 
to be considered as this information may inﬂuence outcomes of FAP- 
targeted interventions. 
Finally, we explored the diagnostic potential of this assay and 
showed that it is a sensitive, simple, robust and speciﬁc system to 
measure elevated soluble or cellular FAP activity in disease states. 
Only a very small volume of ﬂuid is required, making it useful in 
clinical or preclinical settings with limited sample resources and the 
enzyme activity was preserved over numerous freeze–thaw events, 
suggesting that both fresh and archived samples can provide accurate 
data. 
The importance of FAP in epithelial cancers and wound healing 
is established and now these new data indicate that measurable FAP 
activity is in resting states also. The most useful measure of a protease 
is by its enzyme activity and we are now equipped to detect FAP in 
a sensitive, accurate and speciﬁc manner. In doing so, we can gain 
a greater understanding of the role and diagnostic and therapeutic 
potential of FAP. 
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Fig. 6. Quantitation of tissue-derived baboon and human FAP and DPP4 activity. (A) FAP enzyme activity was quantiﬁed in organ homogenates derived from non-diseased baboons 
and humans, showing highest FAP levels in baboon skin, bladder, epididymis, tongue and nerve. (B) DPP4 activity levels in the same baboon organs, showing highest DPP4 levels 
in baboon kidney, adrenal, seminal gland, epididymis and thymus. Horizontal bars are means and error bars depict SEM. 
50 Fiona M. Keane et al. / FEBS Open Bio 4 (2014) 43–54 
Fig. 7. FAP enzyme activity in pregnancy, time of day and disease. (A) Circulating mouse FAP activity. (B) Circulating baboon FAP activity. (C) Tissue-derived FAP activity from 
baboon tumour mass and related lymph nodes (LN), skin and uterus from diseased baboons compared with non-diseased. FAP activity is expressed as pmol AMC released from 
substrate 3144-AMC / min / ml (ﬂuids) or per mg of total protein (organs). Horizontal bars are means and error bars depict SEM. * Denotes p- value < 0.05. 
4
4
w
c. Materials and methods 
.1. Reagents 
Substrate 3144-aminomethylcoumarin (AMC) is a low molecular 
eight ﬂuorogenic substrate [ 57 ]. The lyophilised powder was re- 
onstituted in dimethyl sulfoxide (DMSO) to a stock concentration of 10 mM and aliquoted for storage at −20 ◦C. 30 μl used per well of 
a working solution of 0.5 mM in PBS gave a ﬁnal substrate concen- 
tration of 150 μM per assay. Substrate H-Gly-Pro-AMC (Mimotopes, 
VIC, Australia and Bachem, Switzerland) detects DPP4 preferentially 
in non-reducing conditions at pH 7.8 and room temperature. This sub- 
strate was prepared to a stock concentration of 2 mM in 10% methanol 
in Tris-EDTA buffer [ 25 ]. 50 μl of substrate was added per well to give 
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Fig. 8. Elevated FAP activity and protein in human liver disease. (A) Circulating FAP activity in patients with alcoholic liver disease (ALD) compared to age-, gender- and alcohol 
intake-matched non-diseased (ND) patients. ** Denotes p- value < 0.01. (B) FAP activity in non-diseased (ND) and cirrhotic liver explants from patients ALD or PBC. ***,**** Denotes 
p- value < 0.001 and < 0.0001, respectively. (C–F) FAP protein in ALD and PBC human livers. Unreduced / unboiled 3–8% Tris-Acetate SDS–PAGE with Western blot analysis using 
anti-FAP monoclonal antibody, F19 showed FAP bands at 120 and 150 kDa. GAPDH served as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a ﬁnal assay substrate concentration of 1 mM. A stock concentration
of 5 mM AMC standards (Mimotopes, VIC, Australia) in DMSO was
prepared and stored at 4 ◦C. From a 20 μM working solution in PBS,
30 μl was added to 70 μl of PBS to create the ﬁrst AMC standard
of 600 pmol AMC. Doubling dilutions were made in PBS in 96-well
plates to prepare a linear standard curve of AMC ﬂuorescence, from
which all samples were interpolated. 
4.2. Sample collection and preparation 
All ﬂuids and organs tested for mouse, baboon and human are
summarised in Supplemental Tables 1–3 , respectively. Mouse: C57Bl /
6 mouse blood was drawn into EDTA- or heparin-coated collectiontubes and cells were removed by centrifugation to collect clear yel-
low plasma. For serum, blood was collected in clotting tubes be-
fore centrifugation. Bile was collected from gall bladders using a 25
gauge needle and brief centrifugation. C57Bl / 6 mouse organ collec-
tion and homogenisation have been described previously [ 25 ] and
all mouse studies conformed to Australian National Health and Med-
ical Research Council (NHMRC) regulations and were approved by
the University of Sydney Animal Ethics Committee. Baboon: Papio
hamadryas baboon tissue and ﬂuid samples from the Australian Na-
tional Baboon Colony were collected at autopsy after euthanasia in
accordance with the Australian NHMRC guidelines under Sydney Lo-
cal Health District Animal Welfare Committee approvals. Fluids were
prepared as described for mice above. The veterinary post-mortem
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 nd histopathology reports are summarised in Supplemental Table 
 . Type 1 diabetes was induced in these animals as described pre- 
iously [ 72 ]. Human: Non-diseased human serum / plasma derived 
rom male and female local volunteers aged between 21 and 55. The 
lasma from FAP Ser363Leu variant individuals was obtained with 
ritten informed consent and was in accordance with the Declara- 
ion of Helsinki protocols and approved by the local institution [ 59 ]. 
uman bile ( n = 6) was collected from explant gall bladders of liver 
ransplant recipients. Sera from 29 alcoholic liver cirrhotic patients 
age range 33–71 and three quarters male) were compared with con- 
rol samples from heavy drinkers without liver disease and matched 
or gender, age and alcohol consumption ( Supplemental Table 4 ). Hu- 
an cirrhotic liver tissues were explant biopsies obtained from liver 
ransplant recipients, all at end-stage Child-Pugh class C cirrhosis 
ith published pathology parameters [ 73 ]. ALD patients had an av- 
rage age 49.3 ± 8 (range 34–60; 9 males) and PBC patients had 
n average age 51.7 ± 13.3 (range 27–67; 10 females and 2 males). 
on-diseased liver donors had an age range of 6–58 and mixed gen- 
ers, as described previously [ 7 , 73 ]. All samples from humans were 
btained after written informed consent and in accordance with Aus- 
ralian NHMRC guidelines under Sydney Local Health District Human 
esearch Ethics Committee (HREC) approvals and were in accordance 
ith the Helsinki Declaration of 1975. 
Tissue Lysis: Fresh frozen tissue was homogenized in ice-cold lysis 
uffer: 50 mM Tris-HCl pH 7.6, 1 mM EDTA, 10% glycerol, 1% Triton- 
114, with complete protease inhibitors (Roche, Basel, Switzerland). 
rotease inhibitors are required to preserve FAP enzyme activity by 
reventing proteolytic breakdown during cell lysis. Lysis buffer was 
dded at a ratio of 1:10 wet weight:total volume and homogenised us- 
ng a PT2100 Polytron homogeniser (Kinematica, Switzerland). Sam- 
les were then centrifuged at 14,000 rpm at 4 ◦C for 20 min and the 
oluble supernatant was transferred into a fresh tube, taking care to 
void the lipid layer. Total protein in baboon and human tissue lysates 
as quantiﬁed using the BCA assay (Thermo Scientiﬁc, Waltham, MA, 
SA). FAP activity was calculated as pmol AMC released from the 
144-AMC substrate per min per mg of total protein (baboon, human). 
ouse organ homogenates were not quantiﬁed for total protein con- 
entration [ 25 ], so FAP activity was calculated as pmol AMC / min / mg 
et weight of tissue. 
.3. Enzyme assays 
Black 96-well plates (Greiner Bio-one, Germany) contained dupli- 
ate AMC standards ranging from 600 to 0 pmol with ﬂuid and organs 
ssayed in triplicate. All ﬂuid samples were added at a minimum 
olume of 5 μl. For volumes below 5 μl, pre-dilutions were made. 
peciﬁcally, 5 μl of a 1 / 100, 1 / 50, 1 / 10, 1 / 5 and 1 / 2 dilution gave
 total plasma volume of 0.05, 0.1, 0.5, 1.0, 2.5 μl, respectively. After 
ptimisation, 5 μl of a 1 / 5 dilution of plasma / serum was routinely 
ssayed. Negative control / blank wells contained lysis buffer or PBS 
or organ homogenates or plasma, respectively, along with substrate. 
he plate was read in a Polarstar plate reader (BMG Labtech, Ger- 
any) at excitation of 355 nm and emission of 450 nm every 5 min 
or 1 h at 37 ◦C (FAP assay) or every 2 min for 30 min at 24 ◦C (DPP4
ssay). 
For FAP Enzyme Activity Assay of baboon and human tissue sam- 
les, the volume required to give 100 μg of total protein was added 
er well. For mouse tissue samples, 10 μl of tissue lysate was added 
er well. In all cases, the volume was made to a total of 70 μl with 
BS before adding 30 μl of 500 μM substrate 3144-AMC to detect 
oluble, intracellular and membrane bound forms of active FAP from 
issue lysates. The limit of detection of this substrate on recombi- 
ant human FAP (R&D Systems, Minneapolis, USA) was 15 pg, which 
s equivalent to 0.3 pmol AMC / min / ml. Replicate analysis showed 
nter- and intra-assay coefﬁcient of variation of 19.7 ± 8.35% and 
.2 ± 3.5%, respectively for the soluble human FAP activity assay. For DPP4 Enzyme Activity Assay of baboon tissue samples, the vol- 
ume required to give measureable DPP4 activity was optimized as 
follows: total protein amounts of 10 μg (adrenal and kidney), 20 μg 
(spleen), 30 μg (seminal gland), 40 μg (gall bladder, small intes- 
tine, skeletal muscle and pancreas), 50 μg (bladder, colon, liver, lung, 
lymph node, ovary, prostate, salivary gland, stomach, testis, thymus 
and thyroid), 60 μg (epididymis and heart) and 80 μg (aorta, adipose, 
nerve, skin, tongue) were added per well. In all cases, the volume 
was made to a total of 50 μl with PBS before adding 50 μl of 2 mM 
H-Gly-Pro-AMC (Mimotopes, Australia and Bachem, Switzerland). 
4.4. Bile assay 
5 μl of a 1 / 5 dilution of bile was added to 45 μl of TE buffer and
50 μl of H-Ala-Pro-AFC (Bachem, Switzerland). Fluorescence gener- 
ated was measured at excitation 400 nm and emission 510 nm and 
DPP4 levels were expressed as the change in ﬂuorescence over time 
(  Fluor / min / ml). 
4.5. Data analysis 
Using the BMG plate reader software (Omega Mars, BMG Labtech, 
Germany), the values for each well were blank-corrected and trip- 
licates were averaged. The standard curve for ﬂuorescence of AMC 
standards was linear for the concentration range of 0–600 pmol AMC 
and there was no change in ﬂuorescence over the time-course of 
the assay. All samples were then interpolated from within this range 
and enzyme activity was expressed as pmol AMC released per min. 
This value was then corrected for volume of plasma / serum, per mg 
of total protein (baboon and human) or per mg of wet weight of 
tissue (mouse). Statistical analysis and graphing including standard 
curves used GraphPad Prism 6. Data were analysed by unpaired t -test 
(Mann–Whitney) and signiﬁcance was assigned to p -values less than 
0.05. 
4.6. Multiple sequence alignment 
The FAP protein sequences for human (Q12884), chim- 
panzee (H2QIW2), mouse (P97321) and rat (Q8R492) were ob- 
tained from www.uniprot.org . The baboon genome is undergo- 
ing sequencing ( https: // www.hgsc.bcm.edu / non-human-primates / 
baboon-genome-project ), so the FAP protein sequence predicted from 
the gene sequence from the olive baboon ( Papio anubis ) was obtained 
from NCBI (Gene ID:101023556). All ﬁve sequences were aligned 
by ClustalW ( http: // www.ebi.ac.uk / Tools / msa / clustalw2 / ) and pair 
wise identity scores for both the full length protein and the enzymatic 
hydrolase domain alone were calculated. 
4.7. Human liver Western blotting 
Frozen human liver tissues were weighed and homogenized on ice 
as above. Protein was quantiﬁed and incubated on ice for 10 min in the 
presence of 1 × lithium dodecyl sulphate (LDS) sample buffer (Invit- 
rogen, Carlsbad, CA, USA) prior to gel loading. Protein samples were 
subjected to unreduced and unboiled 3–8% Tris-Acetate SDS–PAGE 
at 150 V for 60 min in 1 × Tris-Acetate SDS–PAGE running buffer 
(NuPAGE, Invitrogen), then transferred to a polyvinylidene ﬂuoride 
(PVDF) membrane (Schleicher & Schull, Dassel, Germany) and im- 
munoblotted with mouse anti-FAP monoclonal antibody (mAb), F19. 
After detection of FAP protein, membranes were blocked overnight 
and re-probed with anti-GAPDH mAb. Densitometry analysis used 
the program ImageJ. 
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